DEF 14A: Lineage Cell Therapeutics Seeks Shareholder Approval for Director Elections, Auditor Ratification, and Executive Compensation

Lineage Cell Therapeutics is holding its annual shareholder meeting on June 11, 2024, to vote on the election of directors, ratification of auditors, and executive compensation.

Summary

• Lineage Cell Therapeutics is holding its 2024 annual meeting of shareholders on June 11, 2024, in Carlsbad, CA.
• Shareholders will vote on the election of eight directors, the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
• The board of directors recommends voting for all director nominees and for Proposals 2 and 3.
• The record date for determining shareholders eligible to vote is April 19, 2024, with 188,798,145 common shares outstanding on that date.
• The proxy materials were first sent or made available to shareholders on or about April 29, 2024.
• Shareholders can vote via the Internet, telephone, or mail, with deadlines for electronic and telephonic votes set for June 10, 2024, at 11:59 p.m. Eastern Time.
• The board of directors has adopted stock ownership guidelines requiring directors to hold at least 10,000 common shares three years following their election.
• The company's Audit Committee has selected WithumSmith+Brown, PC as its independent registered public accounting firm.
• The audit fees billed by Withum for the audit of the company's annual consolidated financial statements were $633,955 for 2023 and $549,049 for 2022.
• The company's executive compensation programs are designed to attract, motivate, and retain highly qualified executives, align management and shareholder interests, reward superior performance, and compensate executives at levels competitive with peer companies.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral tone. The company is taking steps to improve corporate governance and sustainability, which is positive. The loss of a board member is a negative, but overall the document presents a stable and well-managed company.

Positives

• The company has a clear corporate governance structure with independent directors and various committees overseeing key areas such as audit, compensation, and nominating and corporate governance.
• The company is committed to sustainability and has established a task force to focus on corporate responsibility and sustainability matters.
• The company has implemented a Code of Ethics and insider trading policy to promote ethical conduct and prevent improper trading activities.
• The company's Board has adopted stock ownership guidelines requiring directors to hold at least 10,000 common shares three years following the date of their election to the Board.
• The company's executive compensation programs are designed to attract, motivate, and retain highly qualified executives.

Negatives

• The company incurred legal expenses on behalf of certain parties related to a lawsuit challenging the Asterias Merger, which could be viewed negatively.
• The company paid $3.53 million in cash as part of a settlement related to a lawsuit challenging the Asterias Merger.
• The company's former SVP Clinical and Medical Affairs, Dr. Hogge, separated from the company on November 30, 2023.

Risks

• The company faces risks related to information security and cybersecurity, which are overseen by the Audit Committee.
• The company's success depends on its ability to attract, motivate, and retain qualified executives.
• The company's executive compensation programs are subject to shareholder advisory votes, which could impact future compensation decisions.
• The company's financial performance and capital resources could impact its ability to make compensation decisions.

Future Outlook

The document does not provide a detailed future outlook, but it outlines the matters to be voted on at the annual meeting, which will influence the company's direction.

Management Comments

• Brian M. Culley, Chief Executive Officer and Director, signed the notice of the annual meeting.
• The Board believes that good corporate governance is important to ensure that Lineage is managed for the long-term benefit of its shareholders.

Industry Context

Lineage Cell Therapeutics operates in the biotechnology industry, specifically focusing on cell therapy. The proxy statement provides insights into the company's governance, executive compensation, and relationships with its auditors and shareholders, which are all important factors for investors in this sector.

Comparison to Industry Standards

• The peer group used for evaluating executive compensation includes companies like 4D Molecular Therapeutics, Fate Therapeutics, and Geron Corporation, indicating that Lineage benchmarks itself against other clinical-stage biopharmaceutical companies.
• The criteria for selecting the peer group included companies operating in the biopharmaceutical/biotechnology industry with fewer than 150 employees, market capitalization between $150 million and $750 million, and a lead development program in Phase 2.
• The company's non-employee director compensation program is assessed annually using market data provided by an independent consultant, Anderson Pay Advisors, LLC.

Management Changes

Corporate Governance

Legal Proceedings

• A putative class action lawsuit challenging the Asterias Merger was settled in February 2023, with the company and certain insurers paying $10.65 million into a fund for the benefit of the purported class.

Related Party Transactions

• Broadwood purchased 6,730,770 common shares and Don M. Bailey purchased approximately 100,000 common shares in a registered direct offering that closed on February 8, 2024.
• The company incurred legal expenses on behalf of Neal Bradsher and Broadwood related to lawsuits challenging the Asterias Merger.
• The company owned shares of Oncocyte common stock, and Mr. Bradsher may be deemed to beneficially own shares owned by Broadwood, which may be deemed to be the beneficial owner of 19.99% of the outstanding common stock of OncoCyte.

Stakeholder Impact

• The election of directors will impact the leadership and strategic direction of the company, affecting shareholders, employees, and other stakeholders.
• The advisory vote on executive compensation allows shareholders to express their views on the company's compensation practices.
• The company's commitment to sustainability and ethical business conduct impacts the community and environment in which it operates.
• The company's risk management programs are designed to ensure compliance with applicable laws and regulations, protecting the interests of stakeholders.

Next Steps

• Shareholders will vote on the proposals outlined in the proxy statement at the annual meeting on June 11, 2024.
• The company will announce preliminary voting results at the meeting and file a Current Report on Form 8-K with the SEC within four business days after the meeting to report the final voting results.
• The Audit Committee will reconsider whether to retain WithumSmith+Brown, PC for the audit engagement for the 2024 fiscal year if shareholders do not ratify the selection.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, corporate governance, audit committee, shareholders, Lineage Cell Therapeutics, WithumSmith+Brown, stock options